Month: November 2020

Karolinska Development’s portfolio company Aprea Therapeutics receives FDA Fast Track designation for eprenetapopt in AML

Written by Customer Service on November 30, 2020. Posted in Public Companies.

STOCKHOLM, SWEDEN – November 30, 2020. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for eprenetapopt in the treatment of patients with TP53 mutant acute myeloid leukemia (AML). The company previously received Breakthrough Therapy, Orphan Drug and Fast Track designations for eprenetapopt in the treatment of patients with TP53 mutant myelodysplastic syndromes (MDS).The FDA’s Fast Track designation is intended to facilitate the development and review of drug candidates that treat serious conditions and address an unmet medical need. A drug candidate that receives Fast Track designation may be eligible for more frequent interaction with the FDA to discuss the drug candidate’s development plan as well as eligibility for accelerated approval...

Karolinska Developments portföljbolag Aprea Therapeutics erhåller Fast Track designation från FDA för behandling med eprenetapopt vid AML

Written by Customer Service on November 30, 2020. Posted in Public Companies.

STOCKHOLM, SVERIGE 30 november 2020. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att den amerikanska läkemedelsmyndigheten FDA har beviljat Fast Track designation för portföljbolaget Aprea Therapeutics läkemedelskandidat eprenetapopt vid behandling av TP53-mutant akut myeloisk leukemi (AML). Bolaget har tidigare erhållit Breakthrough-status, särläkemedelsstatus och Fast Track designation för eprenetapopt vid behandling av TP53-mutant myelodysplastiskt syndrom (MDS).FDA:s Fast Track designation är avsedd att underlätta utvecklingen och den regulatoriska granskningen av läkemedelskandidater som adresserar allvarliga sjukdomstillstånd och tillgodoser betydande medicinska behov. En läkemedelskandidat som erhåller Fast Track designation kan vara berättigad till frekventare interaktion med FDA för att diskutera den fortsatta...

CF Energy Announces Financial Results For The Nine-Month Period ended September 30, 2020

Written by Customer Service on November 30, 2020. Posted in Public Companies.

TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) — CF Energy Corp., (TSX-V: CFY) (“CF Energy” or the “Company”, together with its subsidiaries, the “Group”), an energy provider in the People’s Republic of China (the ”PRC” or “China”), announces that the Company has filed its unaudited condensed interim consolidated financial results for the nine-month period ended September 30, 2020 (“Nine Months in 2020”).Results for the nine-month period ended September 30, 2020Revenue of Nine Months in 2020 was RMB254.2 million (approx. CAD49.2 million), a decrease of RMB62.4 million (approx. CAD12.2 million), or 20%, from RMB316.6 million (approx. CAD61.4 million) for the nine-month period ended June 30, 2019 (“Nine Months in 2019”). Gross profit for Nine Months in 2020 was RMB95.5 million (approx. CAD18.5 million), a decrease of RMB28.5 million (approx....

Acceleration i den digitale udvikling

Written by Customer Service on November 30, 2020. Posted in Public Companies.

Selskabsmeddelelse nr. 1-2020/2130. november 2020Efter et flot 1. halvår 2019/20 og en nedbremsning i aktiviteterne i 2. halvår 2019/20 på grund af COVID-19 pandemien, har vi fokuseret ressourcerne på at styrke vores markedsposition og vores forretningsområder. Med fortsat digital vækst, en markant forstærket salgsledelse samt opkøbet af Response Optimizer er der skabt et stærkt fundament for de kommende år.InterMail er efter en vellykket transformation i regnskabsåret 2019/20 blevet et datadrevet kommunikationshus med fokus på effektfulde løsninger inden for Multichannel Solutions, Digital Marketing Solutions samt Packaging Solutions. InterMail har konkurrencedygtige produkter, services og priser, og dermed er der grundlag for, at vores markedsandel kan øges de kommende år, da InterMail har en mindre andel i et voksende marked inden...

Olainfarm Group maintains its profit forecast, a short term decline in 9 month sales results

Written by Customer Service on November 30, 2020. Posted in Earnings Releases And Operating Results.

In 2020, the Olainfarm Group continued its ongoing activity in major sales markets. The highest sales in nine months in 2020 was in Latvia, reaching 28 738 thousand EUR, which is 232 thousand EUR or 1% higher than the same period year ago. Latvia sales represent 32% in Group revenues. Sales in Russia for the nine months period in 2020 amount to 20 590 thousand EUR which is a decrease from 2019 due to extra one-off shipment at the end of 2019 for consumption in the first quarter 2020 amounting to 6 million EUR.“Covid-19 pandemic and restrictions due to it have brought different challenges our way, but we understand how to tackle them, and are committed to reach our growth plans outlined in the company’s 5-year strategy. As a long-term investment, we have established a subsidiary in Russia, which allows us to get insights from the...

Olainfarm Grupa saglabā peļņas prognozi, 9 mēnešu pārdošanas rezultātos īslaicīgs kritums

Written by Customer Service on November 30, 2020. Posted in Earnings Releases And Operating Results.

2020. gadā Olainfarm Grupa stabili turpināja iesākto darbību galvenajos noieta tirgos. 2020. gada deviņos mēnešos lielākais pārdošanas apjoms bija Latvijā, sasniedzot 28 738 tūkst. EUR, kas ir 232 tūkst. EUR vai 1% vairāk nekā tajā pašā periodā iepriekšējā gadā. Latvijas pārdošanas apjoms veido 32% no Grupas kopējiem ieņēmumiem. Realizācijas apjoms Krievijā 2020. gada deviņos mēnešos ir 20 590 tūkst. EUR, kas ir samazinājums salīdzinājumā ar 2019. gadu, jo iepriekšējā gadā notika būtiskas papildu piegādes, kas bija paredzētas šim gadam.“Covid-19 pandēmija un tās radītie ierobežojumi ir nesuši dažādus izaicinājumus, taču mēs saprotam, kā tos pārvarēt, un esam apņēmības pilni sasniegt mūsu izaugsmes plānus, ko iezīmē uzņēmuma piecu gadu stratēģija. Kā ilgtermiņa ieguldījumu mēs esam izveidojuši meitas uzņēmumu Krievijā, kas sniedz vēl precīzāku...

Water Ways Reports Q3 2020 Financial Results

Written by Customer Service on November 30, 2020. Posted in Earnings Releases And Operating Results.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATESTORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) — Water Ways Technologies Inc. (TSXV: WWT) (“Water Ways” or the “Company“) announces its financial and business results for the three and nine months ended September 30, 2020 (the “Financial Statements“) and is pleased to provide highlights and comments on these results. This press release should be read in conjunction with the Financial Statements and corresponding Managements Discussion & Analysis found at www.sedar.com. The Financial Statements are prepared in accordance with International Financial Reporting Standards (“IFRS“).Ohad Haber, President, CEO and Chairman of the Board of Water Ways, commented: “These are challenging times in the world....

Report from extraordinary general meeting in Active Biotech and adjustment of previously communicated timetable for the rights issue

Written by Customer Service on November 30, 2020. Posted in Public Companies.

An extraordinary general meeting of Active Biotech was held on November 30, 2020.The meeting resolved, in accordance with the board’s proposal, on a new share issue with pre-emptive rights for existing shareholders. Through the rights issue, not more than 72,618,240 new shares are issued. Two existing shares entitle to subscription for one new share. The rights issue is covered by free of charge subscription commitments and issue guarantees of approximately SEK 40.0 million.The subscription price amounts to SEK 1.05 per share. The record date for participation in the rights issue is January 4, 2021. Subscription for the new shares shall be made during the period 7 – 21 January 2021.A prospectus regarding the rights issue will be made public prior to the commencement of the subscription period.Preliminary timetableLast day for trading...

Kommuniké från extra bolagsstämma i Active Biotech samt justering av tidigare kommunicerad tidplan avseende nyemissionen

Written by Customer Service on November 30, 2020. Posted in Public Companies.

Extra bolagsstämma i Active Biotech AB (publ) hölls den 30 november 2020.Stämman beslutade, i enlighet med styrelsens förslag, om nyemission med företrädesrätt för aktieägarna. Genom nyemissionen ges högst 72 618 240 nya aktier ut. Två befintliga aktier berättigar till teckning av en ny aktie. Nyemissionen omfattas av vederlagsfria teckningsåtaganden och emissionsgarantier om cirka 40,0 miljoner kronor.Teckningskursen uppgår till 1,05 kronor per aktie. Avstämningsdag för rätt att delta i nyemissionen är den 4 januari 2021. Teckning av de nya aktierna ska ske under perioden 7 – 21 januari 2021.Ett prospekt avseende nyemissionen kommer att offentliggöras före teckningsperiodens början.Preliminär tidplanSista dag för handel i Active Biotech-aktien inklusive rätt att delta i emissionen infaller den 29 december 2020, istället för den 30 december...

Real People Investment Holdings Limited: Financial Results – Second quarter 2021

Written by Customer Service on November 30, 2020. Posted in Earnings Releases And Operating Results.

Real People Investment Holdings Limited has released its second quarter 2021 earnings on www.realpeoplegroup.co.za.AttachmentUnaudited Condensed Group Financial Statements Q2 – FY2021

Month: November 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals